	销售和管理费用		日
AbbVie	USD 3.58B	316M	2026-03
Agenus	USD 10.56M	13.04M	2025-12
Agios Pharmaceuticals	USD 38.46M	4.51M	2026-03
Alnylam Pharmaceuticals	USD 282.51M	2.55M	2026-03
Amgen	USD 1.58B	354M	2026-03
Astellas Pharma	JPY 234.7B	12.92B	2026-03
AstraZeneca	USD 5.06B	455M	2026-03
Biogen	USD 554.3M	128.2M	2026-03
BioMarin Pharmaceutical	USD 258.28M	63.92M	2026-03
Bristol-Myers Squibb	USD 1.62B	564M	2026-03
Eli Lilly	USD 2.93B	198M	2026-03
Esperion Therapeutics	USD 39.42M	456K	2025-12
Gilead Sciences	USD 1.45B	326M	2026-03
GlaxoSmithKline	GBP 2.12B	558M	2026-03
Incyte	USD 328.1M	62.31M	2026-03
Ionis Pharmaceuticals	USD 151M	21M	2026-03
J&J	USD 6.03B	719M	2026-03
Kyowa Hakko Kirin	JPY 41.07B	2.82B	2026-03
Merck	USD 2.67B	180M	2026-03
Moderna	USD 173M	135M	2026-03
Neurocrine Biosciences	USD 318.5M	16.7M	2026-03
Novartis	USD 3.14B	296M	2026-03
Novartis	USD 3.44B	132M	2025-12
Pfizer	USD 2.92B	1.16B	2026-03
Puma Biotechnology	USD 16.82M	8.15M	2024-09
Regeneron Pharmaceuticals	USD 647.7M	127.3M	2026-03
Roche Holding	CHF 7.28B	3.99B	2025-12
Sanofi	EUR 2.75B	455M	2025-12
Sarepta Therapeutics	USD 54.03M	51.35M	2026-03
Teva Pharmaceutical Industries	USD 1000M	120M	2026-03
Ultragenyx Pharmaceutical	USD 88M	1000K	2026-03
United Therapeutics	USD 156.6M	34M	2026-03
Vertex Pharmaceuticals	USD 493.7M	6.7M	2026-03